Allemannsdata Wiki
Manual search

BAYER AS

Organization number 911268647 · Aksjeselskap

Programmatic access to company data (JSON)

Source: Firmafakta. Data read and page generated 2026-09-12T03:52:54Z. HTML cache: no-store (TTL 0 seconds). Default TTL for Firmafakta JSON/API responses: 60 seconds.

Facts

Source: Firmafakta, with business data from public registers.

organisasjonsnummer:
911268647
navn:
BAYER AS
organisasjonsform:
kode:
AS
beskrivelse:
Aksjeselskap
naeringskode1:
kode:
46.460
beskrivelse:
Engroshandel med apotekvarer og medisinske varer
antallAnsatte:
128
hjemmeside:
www.bayer.no
epostadresse:
firstname.lastname@bayer.com
telefon:
23 13 05 00
forretningsadresse:
adresse:
Drammensveien 288
poststed:
OSLO
postnummer:
0283
kommune:
OSLO
stiftelsesdato:
1964-09-30
registreringsdatoenhetsregisteret:
1995-03-12
aktivitet:
Handel med farmasøytiske produkter, målesystemer for blodsukker,, plantevern og bekjempelsesmidler og industrielle produkter av enhver, art.
vedtektsfestetFormaal:
Drive industri, handel og produksjon.

View the address in Geonorge

Board and other roles

Source: Firmafakta. Also see the separate Brønnøysund lookup under related lookups.

Daglig leder

Regnskapsfører

Revisor

Styre

Owners

Source: Firmafakta shareholder dataset.

  1. BAYER NORWAY AS – 100.0 % (800 shares, share class: Ordinære aksjer)

Fetch a longer owner list

Company holdings

No holdings found.

Grants and support

Sources provided through Firmafakta: Innovation Norway, the EU, the Research Council of Norway and SkatteFUNN.

Innovasjon Norge (0)

No registered grants.

EU-tildelinger (0)

No registered grants.

Forskningsrådet (2)

2 results

  1. id:
    32230
    prosjektnummer:
    246531
    prosjekttittel:
    Targeted Thorium Conjugates (TTC) New Effective Treatments for Cancer
    prosjektstart:
    2015
    prosjektslutt:
    2017
    prosjektansvarlig_navn:
    BAYER AS
    organisasjonsnummer:
    911268647
    sokt_belop:
    Onkologi
    tildelt_belop:
    3.0
    virkemiddel:
    Frittstående prosjekter
    aktivitet:
    Andre frittstående prosjekter
  2. id:
    23796
    prosjektnummer:
    214837
    prosjekttittel:
    Utvikling av farmasøytisk formuleringsteknologi for i.v. administrering av thorium-227 antistoff alfa-emittere
    prosjektstart:
    2012
    prosjektslutt:
    2016
    prosjektansvarlig_navn:
    BAYER AS
    organisasjonsnummer:
    911268647
    sokt_belop:
    Farmasøytisk formulering og teknologi
    tildelt_belop:
    2.99
    virkemiddel:
    Frittstående prosjekter
    aktivitet:
    Andre frittstående prosjekter

SkatteFUNN (3)

3 results

  1. id:
    72180
    innsendt_dato:
    2024-09-01
    prosjektnummer:
    1791
    bedriftsnavn:
    BAYER AS
    prosjekttittel:
    Targeted Alpha Therapy - Platform
    organisasjonsnummer:
    911268647
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    not reported by source
    soknad_godkjent:
    not reported by source
    soknad_avslatt:
    not reported by source
    vedtaksdato:
    na
    prosjekt_fra_ar:
    2024
    prosjekt_til_ar:
    2027
    sammendrag:
    Unleashing the Power of Alpha: Targeted alpha therapy (TAT) is an emerging cancer treatment that delivers high-energy alpha radiation directly to tumors. This innovative approach offers hope for patients with life-threatening or treatment-resistant cancers. Bayer has a strong history in this field, having been the first to approve a targeted radionuclide therapy for prostate cancer in 2014 (Xofigo developed in Norway), showcasing our expertise in the global development and commercialization of such therapies. We believe TAT can address significant unmet medical needs across various cancer types. Our portfolio includes novel approaches that combine alpha radionuclides with antibodies, peptides, and small molecules for multiple cancer indications. We are dedicated to advancing TATs to support patients with challenging tumors.
  2. id:
    69692
    innsendt_dato:
    2023-09-02
    prosjektnummer:
    349441
    bedriftsnavn:
    BAYER AS
    prosjekttittel:
    Prosjekt TAC FiH
    organisasjonsnummer:
    911268647
    fylke:
    Akershus
    kommunenavn:
    Bærum
    poststed:
    LYSAKER
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2023-12-28
    prosjekt_fra_ar:
    2023
    prosjekt_til_ar:
    2025
    sammendrag:
    The power of alpha Chemotherapy is often ineffective against refractory tumors. Bayer scientists are now working to overcome the defenses of the cancer cells in these tumors using radiation. A radioactive ingredient is guided through the body until it reaches its site of action and then releases targeted tumor-destroying radiation at that specific location. This novel radioimmunotherapy approach could be a source of new hope for cancer patients. Paradoxically, the invisible energy used to save lives does so by inducing a destructive effect as it passes through the tissue. Some forms of radiation penetrate deep through the body tissue and can be used to treat tumors. However, they often also damage healthy cells at the same time. Bayer scientists are now working to channel this destructive energy so that it can be directed more effectively against tumors. This requires precise calculation of the radiation dose and targeted delivery to the desired site of action. The scientists are working with the radioactive element actinium-225, an alpha-particle emitting radionuclide which is complexed to a chelator linked to a tumor specific antibody. The alpha radiation is extremely localized; it only penetrates a maximum of two to ten cell layers. Preclinical trials in cell cultures and animal models have already produced promising results demonstrating highly significant inhibition of tumor growth. The scientists are now testing active substances in first in human clinical trials with patients who have prostate cancer or liver cancer and have tumors expressing specific cell surface proteins
  3. id:
    56205
    innsendt_dato:
    2019-09-01
    prosjektnummer:
    308029
    bedriftsnavn:
    BAYER AS
    prosjekttittel:
    Project PSMA-TTC
    organisasjonsnummer:
    911268647
    fylke:
    Viken
    kommunenavn:
    Bærum
    poststed:
    LYSAKER
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2019-11-28
    prosjekt_fra_ar:
    2019
    prosjekt_til_ar:
    2022
    sammendrag:
    The power of alpha Chemotherapy is often ineffective against refractory tumors. Bayer scientists are now working to overcome the defenses of the cancer cells in these tumors using radiation. A radioactive ingredient is guided through the body until it reaches its site of action and then releases targeted tumor-destroying radiation at that specific location. This novel radioimmunotherapy approach could be a source of new hope for patients with prostate cancer. Paradoxically, the invisible energy used to save lives does so by inducing a destructive effect as it passes through the tissue. Some forms of radiation penetrate deep through the body tissue and can be used to treat tumors. However, they often also damage healthy cells at the same time. Bayer scientists are now working to channel this destructive energy so that it can be directed more effectively against tumors. This requires precise calculation of the radiation dose and targeted delivery to the desired site of action. The scientists are working with the radioactive element thorium-227, an alpha-particle emitting radionuclide which is complexed to a chelator linked to a tumor specific antibody. The alpha radiation is extremely localized; it only penetrates a maximum of two to ten cell layers. Preclinical trials in cell cultures and animal models of prostate cancer have already produced promising results demonstrating highly significant inhibition of tumor growth. The scientists are now testing the active substance in initial clinical trials with patients who have prostate tumors expressing prostate specific membrane antigen (PSMA). PSMA is present in almost all tumors and is therefore a highly desirable target for development of targeted alpha therapies.

Subunits

Open positions

count:
0
stillinger:

No results.

Related lookups

How an AI agent should use this page

Ground rule: Navigate with HTML GET links to keep explanations and relationships. Use the page's JSON alternative only when concrete values must be extracted, compared or computed.

How to use the company page

  1. Use the organization number as the stable key.
  2. Distinguish between the company's own facts, roles, owners, holdings and grants.
  3. Follow person and company links to explore the graph; do not assume relations that are not explicitly registered.

Related services

Time: Ownership, roles and status can change. State the source and retrieval time with factual claims.

AI agent? Read the complete navigation and programming guide.